Anzeige
Mehr »
Login
Dienstag, 12.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Wir entschlüsseln die 55 $ pro Aktie Clean-Energy-Chance für SIE!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P4GU | ISIN: US14147L1089 | Ticker-Symbol: XE7C
Tradegate
12.11.24
18:41 Uhr
3,020 Euro
-0,225
-6,93 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CARDIFF ONCOLOGY INC Chart 1 Jahr
5-Tage-Chart
CARDIFF ONCOLOGY INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,9502,99520:26
2,9502,99520:26

Aktuelle News zur CARDIFF ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrCardiff Oncology Inc reports results for the quarter ended in September 30 - Earnings Summary29
DoCardiff Oncology, Inc. - 10-Q, Quarterly Report7
30.10.Cardiff Oncology, Inc.: Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC23
12.08.Earnings call: Cardiff Oncology Q2 2024 update on CRDF-004 trial and finances17
08.08.Cardiff Oncology, Inc. - 8-K, Current Report1
08.08.Cardiff Oncology, Inc. - 10-Q, Quarterly Report1
CARDIFF ONCOLOGY Aktie jetzt für 0€ handeln
01.07.Cardiff Oncology, Inc. - S-8, Securities to be offered to employees in employee benefit plans7
20.06.Cardiff Oncology, Inc. - 8-K, Current Report7
03.06.Cardiff Oncology, Inc. - 8-K, Current Report8
29.05.Cardiff Oncology, Inc.: Cardiff Oncology to Present at the Jefferies Healthcare Conference7
08.04.Cardiff Oncology, Inc.: Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study259RAS-mutated mCRC - In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization...
► Artikel lesen
06.03.Cardiff Oncology, Inc.: Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024309SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
► Artikel lesen
29.02.Cardiff Oncology, Inc.: Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update244- First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite - - Interim topline data...
► Artikel lesen
29.02.Cardiff Oncology, Inc.: Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC497- New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients - - Company...
► Artikel lesen
17.01.Cardiff Oncology, Inc.: Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research280- Findings from the Phase 1b portion of company's Phase 1b /2 study in second-line KRAS-mutated mCRC highlight the safety and promising efficacy of onvansertib in combination with standard-of-care...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1